These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 18007509)
21. Characterization of dihydrofolate reductases from multiple strains of Plasmodium falciparum using mathematical descriptors of their inhibitors. Basak SC; Mills D; Hawkins DM Chem Biodivers; 2011 Mar; 8(3):440-53. PubMed ID: 21404427 [TBL] [Abstract][Full Text] [Related]
22. A search for sources of drug resistance by the 4D-QSAR analysis of a set of antimalarial dihydrofolate reductase inhibitors. Santos-Filho OA; Hopfinger AJ J Comput Aided Mol Des; 2001 Jan; 15(1):1-12. PubMed ID: 11217916 [TBL] [Abstract][Full Text] [Related]
23. Two- and Three-dimensional Quantitative Structure-activity Relationship Models Based on Conformer Structures. Nitta F; Kaneko H Mol Inform; 2021 Mar; 40(3):e2000123. PubMed ID: 32893463 [TBL] [Abstract][Full Text] [Related]
25. Quantitative structure activity relationship study of 2,4,6-trisubstituted-s-triazine derivatives as antimalarial inhibitors of Plasmodium falciparum dihydrofolate reductase. Ojha H; Gahlot P; Tiwari AK; Pathak M; Kakkar R Chem Biol Drug Des; 2011 Jan; 77(1):57-62. PubMed ID: 20958921 [TBL] [Abstract][Full Text] [Related]
26. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Dixon SL; Smondyrev AM; Knoll EH; Rao SN; Shaw DE; Friesner RA J Comput Aided Mol Des; 2006; 20(10-11):647-71. PubMed ID: 17124629 [TBL] [Abstract][Full Text] [Related]
27. Quantitative structure-activity relationships of 2, 4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase. Selassie CD; Gan WX; Kallander LS; Klein TE J Med Chem; 1998 Oct; 41(22):4261-72. PubMed ID: 9784101 [TBL] [Abstract][Full Text] [Related]
28. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents. Singh P; Kaur M; Sachdeva S J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697 [TBL] [Abstract][Full Text] [Related]
29. Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium. Bolstad DB; Bolstad ES; Frey KM; Wright DL; Anderson AC J Med Chem; 2008 Nov; 51(21):6839-52. PubMed ID: 18834108 [TBL] [Abstract][Full Text] [Related]
30. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity. Ng HL; Chen S; Chew EH; Chui WK Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844 [TBL] [Abstract][Full Text] [Related]
31. A new procedure for improving the predictiveness of CoMFA models and its application to a set of dihydrofolate reductase inhibitors. Kroemer RT; Hecht P J Comput Aided Mol Des; 1995 Oct; 9(5):396-406. PubMed ID: 8594157 [TBL] [Abstract][Full Text] [Related]
32. A review of molecular modelling studies of dihydrofolate reductase inhibitors against opportunistic microorganisms and comprehensive evaluation of new models. Tawari NR; Bag S; Degani MS Curr Pharm Des; 2011; 17(7):712-51. PubMed ID: 21395543 [TBL] [Abstract][Full Text] [Related]
33. The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking. Bourne CR; Wakeham N; Webb N; Nammalwar B; Bunce RA; Berlin KD; Barrow WW Biochemistry; 2014 Feb; 53(7):1228-38. PubMed ID: 24495113 [TBL] [Abstract][Full Text] [Related]
34. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Gilbert IH Biochim Biophys Acta; 2002 Jul; 1587(2-3):249-57. PubMed ID: 12084467 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789 [TBL] [Abstract][Full Text] [Related]
36. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors. Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965 [TBL] [Abstract][Full Text] [Related]
37. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents. Tawari NR; Bag S; Raju A; Lele AC; Bairwa R; Ray MK; Rajan MG; Nawale LU; Sarkar D; Degani MS Future Med Chem; 2015; 7(8):979-88. PubMed ID: 26062396 [TBL] [Abstract][Full Text] [Related]
38. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase. Fogel GB; Cheung M; Pittman E; Hecht D J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315 [TBL] [Abstract][Full Text] [Related]
39. Structure-based modeling of dye-fiber affinity with SOM-4D-QSAR paradigm: application to set of anthraquinone derivatives. Bak A; Wyszomirski M; Magdziarz T; Smolinski A; Polanski J Comb Chem High Throughput Screen; 2014; 17(6):485-502. PubMed ID: 24499310 [TBL] [Abstract][Full Text] [Related]
40. QSAR analysis of 2,4-diaminopyrido[2,3-d]pyrimidines and 2,4-diaminopyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. Jain P; Soni LK; Gupta AK; Kashkedikar SG Indian J Biochem Biophys; 2005 Oct; 42(5):315-20. PubMed ID: 23923540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]